Lucid Diagnostics (LUCD) Panoramica del titolo
Lucid Diagnostics Inc. opera negli Stati Uniti come società di tecnologia diagnostica medica in fase commerciale. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 0/6 |
| Crescita futura | 2/6 |
| Prestazioni passate | 0/6 |
| Salute finanziaria | 5/6 |
| Dividendi | 0/6 |
LUCD Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
IN
Community Contributor
Poised for success
Lucid Diagnostics' EsoGuard is a novel screening tool for esophageal cancer. It is relatively non-invasive and may become widely accepted soon.
View narrativeUS$5
FV
80.0% sottovalutato sconto intrinseco94
users have viewed this narrative1users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
Concorrenti di Lucid Diagnostics Inc.
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | US$1.00 |
| Massimo di 52 settimane | US$1.63 |
| Minimo di 52 settimane | US$0.90 |
| Beta | 1.07 |
| Variazione di 1 mese | 4.09% |
| Variazione a 3 mesi | -29.08% |
| Variazione di 1 anno | -14.53% |
| Variazione a 3 anni | -27.54% |
| Variazione a 5 anni | n/a |
| Variazione dall'IPO | -91.50% |
Notizie e aggiornamenti recenti
Aggiornamento narrativa • Jul 07
LUCD: Higher Future P/E Assumptions Will Reflect Medicare Reimbursement Upside Potential
Analysts have lowered their price target on Lucid Diagnostics to $2 from $3, reflecting updated assumptions on revenue growth, profitability, and discount rates following recent quarterly results and continued uncertainty around Medicare coverage. Analyst Commentary Recent research on Lucid Diagnostics highlights a more cautious stance from several bearish analysts following the latest quarterly update.
Aggiornamento narrativa • Jun 23
LUCD: Medicare Coverage Decision Will Drive Constructive Future Repricing Potential
Lucid Diagnostics’ analyst price target has moved in a mixed fashion recently, with one firm cutting its target to $2 from $3 after a Q1 revenue miss and ongoing Medicare coverage uncertainty, while other analysts cite continued commercialization efforts as support for maintaining a constructive view on the stock. Analyst Commentary Recent Street research on Lucid Diagnostics reflects a mix of caution and optimism, with some analysts trimming price targets after the Q1 revenue shortfall, while others highlight ongoing commercialization work and the potential impact of future Medicare coverage decisions on valuation.Aggiornamento narrativa • Jun 04
LUCD: Medicare Coverage Decision And Commercial Ramp Will Drive Future Repricing
Analysts have adjusted their views on Lucid Diagnostics with a lower blended price target, reflecting a mix of reduced expectations, such as Maxim's cut to $2 from $3 after a Q1 revenue miss and ongoing uncertainty around Medicare coverage, balanced against support for the company's continued commercialization efforts. Analyst Commentary Bullish analysts continue to frame Lucid Diagnostics as an early commercial story where execution on test adoption and payer coverage could be important drivers for the stock.Recent updates
Aggiornamento narrativa • Jul 07
LUCD: Higher Future P/E Assumptions Will Reflect Medicare Reimbursement Upside Potential
Analysts have lowered their price target on Lucid Diagnostics to $2 from $3, reflecting updated assumptions on revenue growth, profitability, and discount rates following recent quarterly results and continued uncertainty around Medicare coverage. Analyst Commentary Recent research on Lucid Diagnostics highlights a more cautious stance from several bearish analysts following the latest quarterly update.Aggiornamento narrativa • Jun 23
LUCD: Medicare Coverage Decision Will Drive Constructive Future Repricing Potential
Lucid Diagnostics’ analyst price target has moved in a mixed fashion recently, with one firm cutting its target to $2 from $3 after a Q1 revenue miss and ongoing Medicare coverage uncertainty, while other analysts cite continued commercialization efforts as support for maintaining a constructive view on the stock. Analyst Commentary Recent Street research on Lucid Diagnostics reflects a mix of caution and optimism, with some analysts trimming price targets after the Q1 revenue shortfall, while others highlight ongoing commercialization work and the potential impact of future Medicare coverage decisions on valuation.Aggiornamento narrativa • Jun 04
LUCD: Medicare Coverage Decision And Commercial Ramp Will Drive Future Repricing
Analysts have adjusted their views on Lucid Diagnostics with a lower blended price target, reflecting a mix of reduced expectations, such as Maxim's cut to $2 from $3 after a Q1 revenue miss and ongoing uncertainty around Medicare coverage, balanced against support for the company's continued commercialization efforts. Analyst Commentary Bullish analysts continue to frame Lucid Diagnostics as an early commercial story where execution on test adoption and payer coverage could be important drivers for the stock.Aggiornamento narrativa • Apr 25
LUCD: Higher Future P/E Assumptions Will Support Upside Despite Execution Risks
Analysts have lifted their price target on Lucid Diagnostics by $0.75, citing updated assumptions around the discount rate, revenue growth, profit margins, and a higher future P/E multiple as the key drivers of the change. Analyst Commentary While the higher price target reflects updated modeling assumptions, bearish analysts still flag several areas of concern that readers should keep in mind when thinking about Lucid Diagnostics.Aggiornamento narrativa • Apr 11
LUCD: Revised Outlook Suggests VA Contract Will Support Future Repricing
Analysts have adjusted their price target on Lucid Diagnostics from $8.25 to $9.00, reflecting updated assumptions on revenue growth, profitability, discount rate, and future P/E expectations. Analyst Commentary Recent research highlights a constructive tone around Lucid Diagnostics, with bullish analysts pointing to updated assumptions on revenue growth, profitability, discount rate, and future P/E expectations as key reasons behind the higher price target of US$9.00.
Nuova narrativa • Apr 01
Poised for success
Lucid Diagnostics' EsoGuard is a novel screening tool for esophageal cancer. It is relatively non-invasive and may become widely accepted soon.Aggiornamento narrativa • Mar 27
LUCD: VA Contract Will Drive Broader Future Adoption And Repricing
Analysts have raised their price target for Lucid Diagnostics to $8.25. This reflects updated views on fair value, discount rate, revenue growth, profit margin, and a very high anticipated future P/E multiple.Aggiornamento narrativa • Mar 12
LUCD: VA Contract Will Expand Screening Access And Support Future Upside
Analysts have modestly adjusted their price target for Lucid Diagnostics to reflect slightly updated assumptions on discount rate, revenue growth, profit margin, and future P/E, while keeping their overall fair value estimate steady at $2.50. What's in the News Lucid Diagnostics received a contract from the U.S. Department of Veterans Affairs for its EsoGuard Esophageal DNA Test, aimed at expanding access to esophageal precancer testing across the VA healthcare system, which serves more than 9,000,000 enrolled veterans annually (Key Developments).Aggiornamento narrativa • Feb 26
LUCD: VA Screening Access And Safety Data Will Support Future Upside
Analysts kept their Lucid Diagnostics price target steady at $2.50, pointing to largely unchanged fair value and P/E assumptions, with only small tweaks to the discount rate, revenue growth, and profit margin inputs behind their models. What's in the News Lucid Diagnostics secured a U.S. Department of Veterans Affairs contract for its EsoGuard Esophageal DNA Test, making the test available across the VA's national integrated healthcare system that serves more than 9 million enrolled veterans each year (Key Developments).Aggiornamento narrativa • Feb 11
LUCD: VA Screening Contract And Real World Data Will Support Future Upside
Analysts have modestly revised their price target on Lucid Diagnostics, citing adjusted assumptions for the discount rate, revenue growth, profit margin, and future P/E that maintain a fair value estimate of $2.50. What's in the News Lucid Diagnostics secured a U.S. Department of Veterans Affairs contract for its EsoGuard Esophageal DNA Test, giving VA hospitals and facilities nationwide a single procurement framework and expanding access across the system that serves more than nine million enrolled veterans annually (Key Developments).Aggiornamento narrativa • Jan 27
LUCD: VA Contract And Real World Screening Data Will Support Future Upside
Analysts have adjusted their price target for Lucid Diagnostics slightly, maintaining fair value at about US$2.50 while fine tuning assumptions on the discount rate, revenue growth, profit margins and future P/E to reflect updated views on the company’s risk profile and earnings power. What's in the News Lucid Diagnostics secured a contract with the U.S. Department of Veterans Affairs for its EsoGuard Esophageal DNA Test, expanding access to esophageal precancer testing across the VA system, which serves more than 9,000,000 enrolled veterans annually (Key Developments).Seeking Alpha • Jan 26
Lucid Diagnostics: Green Flags, But Dilution And Friction Keep Me Neutral
Summary Lucid offers an office-based esophageal precancer screening. The FDA cleared EsoCheck sampling plus EsoGuard NGS epigenetic assay to triage EGD referrals. In my view, their core upside hinges on broader Medicare coverage. The recent CAC support and 45-day notice suggest improving odds on this front. LUCD’s Q3 2025 showed 2,841 tests and $7.1 million in pro-forma revenues billed. But, only $1.2 million could be conservatively recognized. So, there’s still considerable friction for LUCD’s underlying business. Fortunately, real-world evidence looks promising, and the VA FSS contract is a green flag. I think LUCD is heading in the right direction. But it still sports a premium valuation despite its several uncertainties and dilution risks. So I remain neutral on the stock. Read the full article on Seeking AlphaAggiornamento narrativa • Jan 13
LUCD: Real World Screening Data Will Support Stronger Long-Term Profit Potential
Analysts have slightly reduced their price target on Lucid Diagnostics, citing updated assumptions that keep fair value steady at $2.50 while reflecting small adjustments to the discount rate, revenue growth, profit margin and future P/E expectations. What's in the News New real world data on Lucid Diagnostics EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device cover 11,991 at risk patients over 18 months of routine clinical use between January 2023 and June 2024 (medRxiv preprint).Aggiornamento narrativa • Dec 14
LUCD: New Screening Data Will Support Stronger Long-Term Profit Potential
Analysts have raised their price target on Lucid Diagnostics by approximately 25 percent to reflect higher projected revenue growth, slightly improved long term profitability, and a modestly higher valuation multiple despite a small uptick in the assumed discount rate. What's in the News Reported new 18-month real-world data in 11,991 at-risk patients using EsoGuard and EsoCheck for nonendoscopic Barrett's esophagus screening, supporting their utility as scalable, noninvasive tools in routine clinical practice (company announcement) Study authors highlighted excellent safety and tolerability, with EsoCheck achieving a 95% technical success rate, most procedures completed in under two minutes, and no serious adverse events (company announcement) Most patients in the analysis met U.S. gastroenterology society guideline criteria for Barrett's esophagus screening, indicating appropriate physician adoption of EsoGuard and EsoCheck (company announcement) Valuation Changes Fair Value: risen moderately from 2.0x to 2.5x, reflecting a higher implied valuation multiple on forward fundamentals.Articolo di analisi • Dec 13
Is Lucid Diagnostics (NASDAQ:LUCD) Using Too Much Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Nuova narrativa • Apr 12
Expanded Reimbursement And Cash-Pay Programs Will Open Future Markets
Expanding reimbursement coverage and leveraging NCCN guidelines are strategies expected to enhance revenue and credibility with payers.Articolo di analisi • May 09
We're A Little Worried About Lucid Diagnostics' (NASDAQ:LUCD) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Articolo di analisi • Dec 15
Lucid Diagnostics (NASDAQ:LUCD) Will Have To Spend Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Seeking Alpha • Aug 11
Lucid Diagnostics launches stage II lucid test center in California, Texas, Florida, and Ohio
Lucid Diagnostics (NASDAQ:LUCD) announced on Thursday that its subsidiary, LucidDx Labs, has launched four new Lucid Test Centers in California, Texas, Florida and Ohio. Patients in the metropolitan areas with chronic heartburn can order from their own physician or from a telemedicine physician and can now undergo a brief, non-invasive, office-based test to detect esophageal precancer before it progresses to deadly esophageal cancer, using Lucid’s EsoGuard DNA Esophageal Test. The test centers are staffed with Lucid-employed nurse practitioners who use EsoCheck to collect surface esophageal cells which are sent to LucidDx Labs for EsoGuard testing. (LUCD) has risen ~2% premarket.Articolo di analisi • Jul 07
We're Keeping An Eye On Lucid Diagnostics' (NASDAQ:LUCD) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Rendimenti per gli azionisti
| LUCD | US Medical Equipment | US Mercato | |
|---|---|---|---|
| 7D | -2.9% | -6.0% | 0.2% |
| 1Y | -14.5% | -21.7% | 19.6% |
Ritorno vs Industria: LUCD ha superato il US Medical Equipment che ha restituito -21.7 % nell'ultimo anno.
Rendimento vs Mercato: LUCD ha avuto una performance inferiore al mercato US che ha registrato un rendimento 19.6 % nell'ultimo anno.
Volatilità dei prezzi
| LUCD volatility | |
|---|---|
| LUCD Average Weekly Movement | 8.9% |
| Medical Equipment Industry Average Movement | 8.4% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.2% |
Prezzo delle azioni stabile: LUCD non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato US.
Volatilità nel tempo: La volatilità settimanale ( 9% ) di LUCD è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 2018 | 82 | Lishan Aklog | www.luciddx.com |
Lucid Diagnostics Inc. opera negli Stati Uniti come azienda tecnologica di diagnostica medica in fase commerciale. Si concentra sui pazienti affetti da malattia da reflusso gastroesofageo (GERD) che sono a rischio di sviluppare precancerosi e tumori esofagei, soprattutto l'adenocarcinoma esofageo altamente letale. Il prodotto di punta dell'azienda, l'EsoGuard Esophageal DNA Test, viene eseguito su campioni raccolti con il dispositivo di raccolta delle cellule esofagee EsoCheck, uno strumento di analisi con l'obiettivo di prevenire le morti per EAC attraverso la diagnosi precoce del precancro esofageo nei pazienti GERD a rischio.
Lucid Diagnostics Inc. Riepilogo dei fondamenti
| LUCD statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | US$189.07m |
| Utili (TTM) | -US$58.18m |
| Ricavi(TTM) | US$5.13m |
37.2x
Rapporto P/S-3.3x
Rapporto P/ELUCD è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| LUCD Conto economico (TTM) | |
|---|---|
| Ricavi | US$5.13m |
| Costo del fatturato | US$6.74m |
| Profitto lordo | -US$1.61m |
| Altre spese | US$56.57m |
| Utili | -US$58.18m |
Ultimi utili riportati
Mar 31, 2026
Prossima data di guadagno
n/a
| Utile per azione (EPS) | -0.30 |
| Margine lordo | -31.36% |
| Margine di profitto netto | -1,133.21% |
| Rapporto debito/patrimonio netto | 630.0% |
Come si è comportato LUCD nel lungo periodo?
Vedi performance storica e confrontoAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/07/14 20:18 |
| Prezzo dell'azione a fine giornata | 2026/07/14 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Lucid Diagnostics Inc. è coperta da 5 analisti. 5 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Edward Woo | Ascendiant Capital Markets LLC |
| Mark Massaro | BTIG |
| Kyle Mikson | Canaccord Genuity |